Uses of Lipanthyl 200mg

This is an automatically translated article.

1. What is Lipanthyl 200m? Uses of Lipanthyl 200mg

Lipanthyl medicine 200mg has the main ingredient is Fenofibrate 200mg, belongs to the group of drugs to lower blood lipids. Fenofibrate is a derivative of fibric acid, which alters lipid levels in humans through the activation of peroxisome Proliferator Activated Receptor type α (PPARα).
Through the activation of PPARα, fenofibrate increases the degree of lipid hydrolysis and the elimination of triglyceride-rich particles from the plasma. The effect of the above drug is to reduce LDL and VLDL containing apoprotein B and increase HDL containing apoprotein AI and AII. In addition, by altering the synthesis and catabolism of VLDL components, fenofibrate increases the clearance of LDL-for these substances, which are often present in high concentrations, increase the risk of vascular atherosclerotic events. Coronary artery disease, cerebrovascular disease...
According to research, Fenofibrate can reduce blood cholesterol by 20-25% and reduce blood triglycerides by 40-50%.
An association between hypercholesterolemia and atherosclerosis has been confirmed, as well as a link between atherosclerosis and vascular diseases. Fenofibrate also significantly increased HDL-cholesterol levels by 10-30% in patients. Some other uses of the drug:
The effect of urinary uric acid excretion has been demonstrated in patients with hyperlipidemia, significantly reducing blood uric acid by about 25%. Fenofibrate can increase apoprotein A1 and decrease apoprotein B, helping to improve the apo A1/apo B ratio, which is also a risk factor for atherosclerosis. The antiplatelet effect of fenofibrate has been demonstrated in animal studies, followed by several human trials as demonstrated by decreased platelet aggregation and several inflammatory factors.

2. Indications and contraindications for taking Lipanthyl 200mg

2.1. Indications Lipanthyl 20m is indicated for the treatment of:
Hypercholesterolemia and hypertriglyceridemia alone or in combination (dyslipidemia types IIa, IIb, III, IV and V) in unresponsive patients with diet and unresponsive to other non-pharmacological treatments. It is especially important to use the drug when there are other associated risk factors, such as high blood pressure and smoking. Treatment of secondary hyperlipoproteinemia: This is also an indication if lipoprotein abnormalities persist despite treatment of the underlying cause (eg, dyslipidemia in diabetes). It should be combined with diet and exercise. 2.2. Contraindications Do not use Lipanthyl in the following cases:
Liver failure: including biliary cirrhosis and liver function abnormalities of unknown cause; Gallbladder disease; Severe chronic kidney disease; Children have other more suitable dosages; Acute pancreatitis or chronic pancreatitis except in cases of acute pancreatitis due to severe hypertriglyceridemia; History of photosensitivity or phototoxicity during treatment with fibrates or ketoprofen; In combination with other fibrates because of the increased risk of side effects. Hypersensitivity to fenofibrate or to any of the excipients listed in the formulation. Relative contraindications: Lactation period; In combination with HCM-CoA reductase inhibitors (statins)

3. Usage and dosage of Lipanthyl 200m

The drug is in the form of capsules, to be taken orally. Should be taken with meals. During treatment, the response to treatment should be monitored by determining serum lipid indices. If a response is not achieved after several months of treatment, additional doses of the drug or other therapeutic measures should be considered.
Adults: The recommended dose is 200mg per day i.e. 1 Lipanthyl 200M tablet. Elderly: For elderly patients, without renal impairment, the usual dosage recommendations are similar to those for adults. In case of renal failure, use according to renal function. Renal Impairment: Dosage should be reduced in patients with renal impairment. Fenofibrate is not recommended in patients with severe chronic kidney disease. Hepatic impairment: Lipanthyl 200M is not recommended in patients with hepatic impairment due to lack of data at present. Children: The safety and effectiveness of fenofibrate in children and adolescents under 18 years of age have not been established. Therefore, the use of fenofibrate in children under 18 years of age is not recommended.

4. Undesirable effects when using Lipanthyl 200m

As with other fibrates, the use of Lipanthyl also causes side effects including:
Cases of muscle damage causing diffuse myalgia, tenderness, and weakness as well as cases of The exception of severe rhabdomyolysis has been reported. Usually this goes away after stopping the medication. Some other adverse effects, which are less common and milder, such as: dyspepsia, increased transaminases, skin reactions such as rash, pruritus, urticaria, photosensitivity have rarely been reported. report. In some cases, even after many months of patients taking the drug with no side effects, photosensitization of the skin such as rashes, blisters, eczema, etc., occurs on areas exposed to the sun. sunlight or artificial UV rays (UV lamps). Some other rare side effects include: Decrease in Hemoglobin, decrease in white blood cell count, immune disorders, headache, dizziness, pulmonary embolism; hair loss, pancreatitis... When side effects occur, you need to stop the drug and immediately notify the doctor, for timely handling measures.

5. Notes when using Lipanthyl 200m

Before taking the drug, it is necessary to inform the doctor about the history of allergies to the drug, the comorbidities and the drugs being used.
For cases of secondary hyperlipidemia can be caused by other causes. But in some of the following cases, you should consider taking fenofibrate such as uncontrolled type 2 diabetes, hypothyroidism, nephrotic syndrome, blood protein disorders, obstructive liver disease, alcoholism. .
Should limit exposure to the sun because it can cause increased sensitivity to light. Take precautions when outdoors and use appropriate sunscreen.
Pregnant women: There are currently no adequate data on the use of fenofibrate in pregnant women. The potential hazard to humans is unknown. Therefore, Lipanthyl should only be used during pregnancy after careful assessment of the benefit and risk to the fetus.
As with other lipid-lowering drugs, the use of Lipanthyl also has a risk of increasing liver enzymes, so it is necessary to periodically evaluate liver enzymes. Temporarily discontinue the drug when there is an increase in liver enzymes.
Serious myopathy has also been reported, so if the course of taking the drug shows signs of myalgia, myalgia, myositis should be examined to rule out myopathy due to Fenofibrate. Patients with potential factors for myopathy or rhabdomyolysis include: Patients over 70 years of age, personal or family history of hereditary muscle disorders, renal failure, hypothyroidism, and alcoholism These may increase the risk of developing rhabdomyolysis. For patients at risk, the benefits and risks of fenofibrate should be carefully weighed.
Because the drug contains lactose, patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.

6. Interactions with other drugs

Oral Anticoagulants: Fenofibrate enhances the effects of anticoagulants and may increase the risk of bleeding. It is recommended that the dose of oral anticoagulants be reduced by approximately one-third of the recommended dose at the start of treatment and then, if necessary, adjusted according to the INR. Cyclosporin: A few cases of severe reversible renal function impairment have been reported with concomitant use of fenofibrate and cyclosporine. Renal function in patients receiving these two combinations should be closely monitored and treatment with fenofibrate should be discontinued in the event of significant changes in laboratory parameters. HMG-CoA reductase inhibitors or other fenofibrates: The risk of myotoxicity is increased if fibrates are combined with HMG-CoA reductase inhibitors or with other fibrates. Where it is necessary to use this combination, caution should be exercised and close monitoring for signs of muscle toxicity. Glitazones: Some reductions in HDL-cholesterol have been observed with concomitant use of fenofibratte and glitazones. Therefore, monitoring of HDL-cholesterol is recommended if the above combination is used and discontinuation if HDL-cholesterol is too low. Hopefully, through the article you have had the necessary information about Lipanthyl 200m. This is a drug prescribed by a doctor, you should not self-medicate.

Please dial HOTLINE for more information or register for an appointment HERE. Download MyVinmec app to make appointments faster and to manage your bookings easily.